Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

a treatment associated with both short- and long-term toxicities.

ALL, the most common form of leukemia in children, is a fast-growing cancer of the white blood cells in which the bone marrow makes a large number of abnormal white blood cells that are unable to develop and fight infection. Important developments over the past 20 years have led to seminal insights about ALL in children, and today nearly 90 percent of children diagnosed with standard-risk ALL are cured. Some treatment regimens for standard-risk ALL include initial infusions of daunorubicin, a type of anthracycline. While effective, continual use of this therapy is associated with potential long-term heart damage, leading researchers to assess whether eliminating or reducing the dosage of daunorubicin during the initial one-month induction therapy period might provide the same level of efficacy as the standard treatment protocol with reduced long-term risk.

In order to assess the efficacy of ALL treatment without daunorubicin during induction therapy, a team of researchers from 20 centers across France and one center in Belgium initiated a multicenter Phase III clinical trial in which 1,128 pediatric patients with standard-risk B-cell ALL were randomized into two treatment arms. Arm A included 560 patients who received a standard dose of daunorubicin during induction therapy, while Arm B included 568 patients who did not receive initial therapy with daunorubicin. Both groups received doxorubicin during delayed intensification (last treatment phase before reaching maintenance) and a standard protocol of 24-month maintenance therapy from December 2000 to June 2010, during which five-year event-free survival (EFS) and overall survival (OS) were assessed.

For those patients treated with daunorubicin, the five-year EFS rate was 92.9 percent, compared to 93.3 percent in the non-daunorubicin arm. Overall survival rates were 97.2 percent and 98.2 percent in the daunorubicin and n
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... Recovery at Recovery Unplugged™—will be delivering a plenary ... Singer/Songwriter's Perspective on the Art of Healing and ... Disorders (NCAD) and Behavioral Healthcare Executive Summit (BHES).     ... name, Mr. Supa’s songs have been recorded by ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... grow at a CAGR of 6.1% to reach ... 2014. , Factors such as advantages of ... healthcare costs owing to minimally invasive surgeries and ... population are driving the global minimally invasive surgical ...
(Date:3/2/2015)... DC (PRWEB) March 02, 2015 Atlantic ... publication of AIS’s Directory of Health Plans: 2015 ... resource available on the U.S. health plan market, with ... in the United States. , Available as a ... Summary” of enrollment trends in quick-view tables and charts, ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 In light ... of anticoagulant Xarelto (rivaroxaban) tablets, Ford & ... may be helpful for future users, but may come ... injuries from taking the drug. The FDA has now ... under Adverse Reactions on Xarelto's label. The term “cytolytic ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
... finds , WEDNESDAY, Feb. 17 (HealthDay News) -- Good ... improve their odds of staying healthy: baked rhubarb may ... garden rhubarb for 20 minutes dramatically boosted levels of ... polyphenols selectively kill or prevent the growth of cancer ...
... Rural areas tend to fare worse than urban locales, ... -- Want to know how healthy your county is? ... ranking of nearly every county in the nation shows ... on where they live. , Researchers from University of ...
... , GREENBRAE, Calif. , Feb. 17 ... of transformational media, announced today the release of Sound Sanctuaries ... Malkin . , Designed to help listeners experience deep inner peace ... moving music by Malkin that he says will "awaken the spirit ...
... N.C. , Feb. 17 MedCath Corporation (Nasdaq: ... they have entered into a definitive agreement to sell substantially ... David,s Healthcare Partnership, L.P. ("St. David,s"). The transaction is expected ... to customary closing conditions and regulatory requirements. , The sale ...
... , ... Services marked the start of 2010 with the official launch of a new state-of-the-art ... industries, this latest addition to the Almac services portfolio is set to revolutionise the ... ...
... MyNursingUniforms ... nursing uniform store. , ... February 17, 2010 -- MyNursingUniforms (MNU), a leader in online retail for nursing uniforms and ... , ,MNU made the expansion to their online store in both the shoe and medical ...
Cached Medicine News:Health News:County-By-County Report Sizes Up Americans' Health 2Health News:County-By-County Report Sizes Up Americans' Health 3Health News:New CD Collections Promise to Create a Sound Sanctuary in Your Home, Office, or Car 2Health News:MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 3Health News:MyNursingUniforms Adds Skechers Brand Name Shoes and Scrubs to Store 2
(Date:3/2/2015)... , March 2, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an emphasis ... announces that Company management will participate in the upcoming ... March 8-11, 2015 at the Ritz Carlton Laguna Niguel ... Jennifer Simpson , PhD, MSN, CRNP, Delcath,s interim President ...
(Date:3/2/2015)... NORTH HOLLYWOOD, Calif. , March 2, 2015 ... improving the quality of life of myeloma patients ... once again declared the month of March to ... IMF first established March as Myeloma Awareness Month ... information about the disease through local community events, ...
(Date:3/2/2015)... DUBLIN , Mar. 02, 2015 Research ... announced the addition of the "Lopinavir - ... , Imagine having your own ... of a button. Used by the ... over 10 years, these searches are the benchmark ...
Breaking Medicine Technology:Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Global Comprehensive Lopinavir Patent Search Online Portal 2015 2
... 4, 2011 WebMD Health Corp. (Nasdaq: WBMD ... deliver a presentation at the UBS 21st Annual Global Healthcare ... ET. Investors, analysts and the general public are ... presentation over the Internet.  The broadcast can be accessed at ...
... K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a ... informed by Hologic, Inc. that the U.S. Food and ... injection).  Makena, commonly referred to as "17P," is the ... risk of preterm birth in women with a singleton ...
Cached Medicine Technology:FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 3FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 4FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 5FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 6FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 7FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 8FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 9FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 10FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 11FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 12
... The electronic, motorized ... for all applications of ... and hard specimens in ... labs. These instruments display ...
... Leica RM2255 rotary microtome, designed for ... and resin-embedded specimens, offers a broad ... research histology laboratory. This microtome meets ... a compact, fully motorized/electronic microtome for ...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user....
... system for specimen surface preparation is the ... attachment Leica SP2600. ,Ultramilling is often a ... microtomy in sample preparation. Especially with difficult ... located side by side in one specimen ...
Medicine Products: